Swiss National Bank Has $71.19 Million Stock Position in United Therapeutics Corporation $UTHR

Swiss National Bank lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 2.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 120,055 shares of the biotechnology company’s stock after purchasing an additional 2,320 shares during the period. Swiss National Bank’s holdings in United Therapeutics were worth $71,190,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. AIA Group Ltd grew its stake in shares of United Therapeutics by 20.9% in the first quarter. AIA Group Ltd now owns 2,415 shares of the biotechnology company’s stock valued at $1,432,000 after buying an additional 417 shares in the last quarter. Arjuna Capital increased its holdings in United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after buying an additional 18 shares during the last quarter. Dorsey Wright & Associates raised its position in United Therapeutics by 113.9% during the first quarter. Dorsey Wright & Associates now owns 10,967 shares of the biotechnology company’s stock worth $6,503,000 after acquiring an additional 5,839 shares in the last quarter. California Public Employees Retirement System raised its position in United Therapeutics by 5.9% during the first quarter. California Public Employees Retirement System now owns 88,289 shares of the biotechnology company’s stock worth $52,354,000 after acquiring an additional 4,933 shares in the last quarter. Finally, Kera Capital Partners Inc. lifted its stake in United Therapeutics by 6.1% in the first quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock valued at $279,000 after acquiring an additional 27 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $535.83 on Wednesday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The company has a market capitalization of $22.75 billion, a price-to-earnings ratio of 19.78, a PEG ratio of 1.77 and a beta of 0.58. The company has a 50-day simple moving average of $550.65 and a 200 day simple moving average of $530.90.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $6.63 earnings per share. Sell-side analysts forecast that United Therapeutics Corporation will post 26.63 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on UTHR shares. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Raymond James Financial initiated coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $644.82.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $568.83, for a total transaction of $5,688,300.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,737,235.08. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 535,379 shares of company stock valued at $299,468,343 over the last 90 days. 8.60% of the stock is currently owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.